Form 8-K - Current report:
SEC Accession No. 0001213900-25-054373
Filing Date
2025-06-13
Accepted
2025-06-13 17:15:07
Documents
14
Period of Report
2025-06-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0245742-8k_klotho.htm   iXBRL 8-K 30067
2 TERMINATION AND RELEASE AGREEMENT ea024574201ex4-1_klotho.htm EX-4.1 30346
  Complete submission text file 0001213900-25-054373.txt   279772

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE klto-20250609.xsd EX-101.SCH 3496
4 XBRL DEFINITION FILE klto-20250609_def.xml EX-101.DEF 26515
5 XBRL LABEL FILE klto-20250609_lab.xml EX-101.LAB 36423
6 XBRL PRESENTATION FILE klto-20250609_pre.xml EX-101.PRE 25139
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0245742-8k_klotho_htm.xml XML 5482
Mailing Address 1115 BROADWAY 12TH FLOOR NEW YORK NY 10010
Business Address 1115 BROADWAY 12TH FLOOR NEW YORK NY 10010 646-916-5315
Klotho Neurosciences, Inc. (Filer) CIK: 0001907223 (see all company filings)

EIN.: 862727441 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41340 | Film No.: 251047687
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)